Mesenteric Fat Lipolysis Mediates Obesity-associated Hepatic Steatosis and Insulin Resistance by Wueest, Stephan et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Mesenteric Fat Lipolysis Mediates Obesity-associated Hepatic Steatosis and
Insulin Resistance
Wueest, Stephan; Item, Flurin; Lucchini, Fabrizio C; Challa, Tenagne D; Müller, Werner; Blüher,
Matthias; Konrad, Daniel
Abstract: Hepatic steatosis and insulin resistance are among the most prevalent metabolic disorders and
tightly associated with obesity and type 2 diabetes. However, underlying mechanism linking obesity
to hepatic lipid accumulation and insulin resistance are incompletely understood. Glycoprotein 130
(gp130) is the common signal transducer of all interleukin 6 (IL-6) cytokines. Herein, we provide evidence
that gp130-mediated adipose tissue lipolysis promotes hepatic steatosis and insulin resistance. In obese
mice, adipocyte-specific gp130 deletion reduced basal lipolysis and enhanced insulin’s ability to suppress
lipolysis from mesenteric but not epididymal adipocytes. Consistently, free fatty acid levels were reduced
in portal but not in systemic circulation of obese knockout mice. Importantly, adipocyte-specific gp130
knockout mice were protected from high fat diet (HFD)-induced hepatic steatosis as well as insulin
resistance. In humans, omental but not subcutaneous IL-6 mRNA expression correlated positively with
liver lipid accumulation (r=0.31; p<0.05) and negatively with euglycemic clamp glucose infusion rate
(r=-0.28; p<0.05). Our results demonstrate that IL-6 cytokine-induced lipolysis may be restricted to
mesenteric WAT and that it contributes to hepatic insulin resistance and steatosis. Therefore, blocking
IL-6 cytokine signaling in (mesenteric) adipocytes may be a novel approach to blunt detrimental fat-liver
crosstalk in obesity.
DOI: https://doi.org/10.2337/db15-0941
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-115888
Accepted Version
Originally published at:
Wueest, Stephan; Item, Flurin; Lucchini, Fabrizio C; Challa, Tenagne D; Müller, Werner; Blüher,
Matthias; Konrad, Daniel (2016). Mesenteric Fat Lipolysis Mediates Obesity-associated Hepatic Steatosis
and Insulin Resistance. Diabetes, 65(1):140-148.
DOI: https://doi.org/10.2337/db15-0941
Mesenteric Fat Lipolysis Mediates Obesity-associated Hepatic Steatosis and 
Insulin Resistance 
 
 
Stephan Wueest1,2, Flurin Item1,2, Fabrizio C. Lucchini1,2,3, Tenagne D. Challa1,2, Werner 
Müller4, Matthias Blüher5 and Daniel Konrad1,2,3 
 
1Division of Pediatric Endocrinology and Diabetology and 2Children Research’s Centre, 
University Children's Hospital, Zurich, Switzerland 
3Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, 
Switzerland 
4Faculty of Life Sciences, University of Manchester, Manchester, U.K. 
5University of Leipzig, Department of Medicine, Leipzig, Germany 
 
 
All correspondence and requests for reprint to: 
Daniel Konrad, MD PhD 
University Children’s Hospital 
Department of Endocrinology and Diabetology 
Steinwiesstrasse 75 
CH-8032 Zurich 
Tel: ++41-44-266 7966; Fax: ++41-44-266 7983 
Email: daniel.konrad@kispi.uzh.ch 
or: 
Stephan Wueest, PhD 
Email: stephan.wueest@usz.ch 
Page 1 of 34 Diabetes
 Diabetes Publish Ahead of Print, published online September 17, 2015
 2
Abstract  
Hepatic steatosis and insulin resistance are among the most prevalent metabolic 
disorders and tightly associated with obesity and type 2 diabetes. However, underlying 
mechanism linking obesity to hepatic lipid accumulation and insulin resistance are 
incompletely understood. Glycoprotein 130 (gp130) is the common signal transducer of 
all interleukin 6 (IL-6) cytokines. Herein, we provide evidence that gp130-mediated 
adipose tissue lipolysis promotes hepatic steatosis and insulin resistance. In obese 
mice, adipocyte-specific gp130 deletion reduced basal lipolysis and enhanced insulin’s 
ability to suppress lipolysis from mesenteric but not epididymal adipocytes. Consistently, 
free fatty acid levels were reduced in portal but not in systemic circulation of obese 
knockout mice. Importantly, adipocyte-specific gp130 knockout mice were protected 
from high fat diet (HFD)-induced hepatic steatosis as well as insulin resistance. In 
humans, omental but not subcutaneous IL-6 mRNA expression correlated positively with 
liver lipid accumulation (r=0.31; p<0.05) and negatively with euglycemic clamp glucose 
infusion rate (r=-0.28; p<0.05). Our results demonstrate that IL-6 cytokine-induced 
lipolysis may be restricted to mesenteric WAT and that it contributes to hepatic insulin 
resistance and steatosis. Therefore, blocking IL-6 cytokine signaling in (mesenteric) 
adipocytes may be a novel approach to blunt detrimental fat-liver crosstalk in obesity. 
 
 
 
 
Page 2 of 34Diabetes
 3
Introduction 
The prevalence of obesity and associated diseases such as insulin resistance 
and hepatic steatosis are increasing to epidemic proportions (1). Yet, underlying 
pathological mechanisms are not fully understood. Although there is evidence that 
interleukin-6 (IL-6) may contribute to the development of fatty liver disease and hepatic 
insulin resistance, its exact role in the pathogenesis of these disorders is the subject of 
intense debate (2-5). IL-6 is secreted by different cells and tissues such as adipocytes, 
immune cells and skeletal muscle thereby modulating metabolism under both 
physiological and pathophysiological conditions (2; 6). To activate its intracellular 
signaling pathways, IL-6 either binds to its membrane-bound receptor (mIL-6R; classic 
signaling) or to its soluble receptor (sIL-6; trans-signaling pathway). Of note, mIL-6R is 
expressed in the liver and immune cells while it is absent in adipocytes (7). In turn, this 
ligand/receptor complex associates with a homodimer of glycoprotein 130 (gp130), 
which is a common signal transducer protein of all IL-6 cytokines (8; 9). Subsequently, 
the JAK/STAT and the ERK1/2 pathway are activated (9; 10).  
In the liver, chronically elevated circulating IL-6 levels were proposed to induce 
insulin resistance and inflammation in mice (11; 12). In contrast, a recent study 
proposed the opposite since it found IL-6 to reduce inflammation and to improve insulin 
sensitivity in the liver (13). Therefore, the hepatic derangements associated with 
elevated IL-6 levels as observed in the former studies (11; 12) may be mediated via an 
indirect effect of IL-6, for example through induction of adipose tissue lipolysis. Indeed, 
IL-6 was shown to induce lipolysis in vivo and in vitro  (14; 15) and  a recent publication 
suggested that IL-6 promotes hepatic insulin resistance indirectly through increased free 
fatty acid (FFA) release from adipose tissue in rodents (16). Of note, obesity-induced IL-
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6 increase was higher in mesenteric fat compared to other adipose depots (17; 18) 
suggesting that IL-6-induced adipose tissue lipolysis may play a distinct role in visceral 
fat. 
In the present study, we sought to determine whether (i) mesenteric adipose 
tissue is more sensitive to IL-6 -induced lipolysis than epididymidal fat and whether (ii) 
IL-6-induced FFA-release from (mesenteric) fat contributes to obesity-associated hepatic 
steatosis and insulin resistance making use of adipocyte-specific gp130 depleted mice. 
 
 
Research Design and Methods 
 
Determination of total liver fat and adipose tissue IL-6 mRNA expression in humans 
IL-6 mRNA expression was measured in abdominal omental and subcutaneous 
adipose tissue (AT) samples obtained in parallel from 63 men (n = 34) and women (n = 
29) who underwent open abdominal surgery for Roux-en-Y bypass, sleeve gastrectomy, 
explorative laparotomy or elective cholecystectomy. Liver and AT biopsies was taken 
during surgery, immediately snap-frozen in liquid nitrogen, and stored at −80°C until 
further preparations. Measurement of total body and liver fat, tissue sample handling 
and analysis of blood samples including measurement of serum adiponectin and leptin 
concentrations has been performed as described previously (19; 20). IL-6 plasma 
concentrations were measured by a high-sensitivity ELISA kit (Quantikine IL-6, R&D 
Systems, Oxford, UK). Insulin sensitivity was assessed with the euglycemic-
hyperinsulinemic clamp method using a previously described protocol (21). Glucose 
infusion rate (GIR) was calculated from the last 45 min of the clamp, during which 
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glucose infusion rate could be kept constant in order to achieve the target plasma 
glucose concentration of 5.5 (± 5%) mmol/L. Therefore, the duration of the clamp varied 
between individuals (range 120-200min). GIR was normalized to lean body mass. In 
premenopausal women, clamp studies were performed during the luteal phase of the 
menstrual cycle. All participants gave their written informed consent before taking part in 
the study. All investigations have been approved by the ethics committee of the 
University of Leipzig (363-10-13122010 and 017-12-230112) and were carried out in 
accordance with the Declaration of Helsinki. 
Human IL-6 mRNA expression was measured by qRT-PCR using Assay-on-
Demand gene expression kit (Hs00985639_m1; Applied Biosystems, Darmstadt, 
Germany), and fluorescence was detected on an ABI PRISM 7000 Sequence Detector 
(Applied Biosystems). IL-6 mRNA expression was calculated relative to the mRNA 
expression of HPRT1 mRNA (Hs01003267_m1; Applied Biosystems). 
 
Animals 
Adipocyte-specific gp130 knockout mice (gp130∆adipo) on a C57BL/6J background 
were generated by crossing gp130 floxed (gp130F/F) mice (22) to animals expressing the 
Cre recombinase controlled by the Adipoq promoter (AdipoqCre mice; purchased from 
The Jackson Laboratory).  
Six weeks-old male mice were fed ad libitum with standard rodent diet (chow) or 
high fat diet (HFD; D12331, Research Diets, New Brunswick, USA) for 12 weeks. HFD 
consisted of 58% of calories derived from fat, 28% from carbohydrate and 16% from 
protein. All protocols conformed to the Swiss animal protection laws and were approved 
by the Cantonal Veterinary Office in Zurich, Switzerland.  
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Glucose clamp studies  
Glucose clamp studies were performed as described (23). Clamps were 
performed in freely moving mice. Glucose infusion rate was calculated once glucose 
infusion reached a more or less constant rate with blood glucose levels at 5 mmol/l (80–
90 min after the start of insulin infusion). Thereafter, blood glucose was kept constant at 
5 mmol/l for 15-20 min and glucose infusion rate was calculated. The glucose disposal 
rate was calculated by dividing the rate of [3-3H]glucose infusion by the plasma [3-
3H]glucose specific activity (24; 25). Endogenous glucose production during the clamp 
was calculated by subtracting the glucose infusion rate from the glucose disposal rate 
(24; 25). In order to assess tissue specific glucose uptake, a bolus (10 µCi) of 2-[1-
14C]deoxyglucose was administered via catheter at the end of the steady state period. 
Blood was sampled 2, 15, 25 and 35 min after bolus delivery. Area under the curve of 
disappearing plasma 2-[1-14C]deoxyglucose was used together with tissue-concentration 
of phosphorylated 2-[1-14C]deoxyglucose to calculate glucose uptake. 
 
Lipolysis assays 
Adipocytes were isolated and lipolysis was assessed as described (26). Isolated 
adipocytes were incubated in the absence or presence of 100 nM insulin, 100 ng/ml 
recombinant murine IL-6 (R&D Systems, Oxford, UK ) or 1 µM isoproterenol (Sigma, 
Buchs, Switzerland) for one hour. FFA levels were measured using the ACS-ACOD-
MEHA method from Wako Chemicals GmbH (Neuss, Germany). 
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Cell size determination 
Cell size of isolated adipocytes was analyzed by a Multisizer™ 3 Coulter 
Counter® as previously described (27). 
 
Blood sampling 
Immediately after euthanasia abdominal cavity was opened and the portal vein 
exposed. It was punctured by a syringe (0.30mm (30G) x 8mm; BD, New Jersey, USA) 
and the blood was collected. Systemic blood was sampled after cardiac puncture using 
similar syringes. Blood was added to an Eppendorf tube with a final concentration of 5 
mM EDTA. After centrifugation, plasma was stored at -80°C upon further processing.     
 
Determination of plasma insulin, triglyceride and free fatty acids 
Plasma triglyceride (TG) and free fatty acid (FFA) levels were determined as 
described elsewhere (28). Plasma insulin levels were measured using an ELISA kit as 
described previously (29). 
 
Western blotting 
Liver or adipose tissue samples were homogenized and Western blotting was 
performed as described previously (30). The following primary antibodies were used: 
anti-gp130, anti-SOCS3 (Santa Cruz Biotechnology, Dallas, TX, USA), anti-phospho 
p38, anti-phospho ERK, anti-ERK  (Cell Signaling, Danvers, MA, USA) and anti-actin 
(Millipore, Billerica, MA, USA). Membranes were exposed in an Image Reader and 
analyzed with Image Analyzer (FujiFilm, Dielsdorf, Switzerland).  
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RNA extraction and quantitative reverse transcription-PCR (RT-PCR) 
Total RNA was extracted using RNeasy Lipid Tissue Mini Kit (Qiagen, Basel, 
Switzerland) and concentration was determined spectrophotometrically (Nanodrop 1000; 
Nanodrop Technologies, Boston, MA). 1 µg of RNA were reverse transcribed with 
Superscript III Reverse Transcriptase (Invitrogen, Basel, Switzerland) using random 
hexamer primer (Invitrogen). Taqman (Applied Biosystems, Rotkreuz, Switzerland) was 
used for real-time PCR amplification.  The following PCR primers (Applied Biosystems) 
were used: TNF-α Mm00443258_m1, IL-6 Mm00446190_m1, F4/80 Mm00802529_m1, 
CD11b Mm00434455_m1, FAS Mm00662319_m1, PPARα Mm00627559_m1, SREBP1 
Mm00550338_m1, SCD-1 Mm01197142_m1, CPT-1 Mm00550438_m1, AOX 
Mm00443579_m1. Relative gene expression was obtained after normalization to 
18sRNA (Applied Biosystems), using the formula 2-∆∆cp (31). 
 
Liver triglyceride and total lipid determination 
Liver tissue (20-30mg) was homogenized in PBS and lipids were extracted in a 
chloroform-methanol (2:1) mixture. Total liver lipids were determined by a 
sulfophosphovanillin reaction as previously described (32). Liver triglyceride levels were 
determined in 50 mg of liver tissue according to the method of Bligh and Dyer (33) and 
quantified with an enzymatic assay (Roche Diagnostics, Rotkreuz, Switzerland). 
 
Histology 
Liver tissues were fixed in 4% buffered formalin and embedded in paraffin. 
Sections were cut and stained with hematoxylin and eosin.   
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Data analysis 
Statistical analyses were performed using Student’s t test or ANOVA with 
Newman-Keuls post-hoc test. In human studies, linear relationships were assessed by 
Spearman Rank correlation analyses. p-Values < 0.05 were considered significant. 
 
 
Results 
 
Similar weight gain and adipogenesis in adipocyte-specific gp130 knockout mice and 
control littermates 
To investigate the role of IL-6-induced lipolysis in metabolic derangements in 
vivo, we generated adipocyte-specific gp130 knockout mice (gp130∆adipo) using the cre-
lox system. As controls, littermate mice with floxed gp130 but absent Cre-recombinase 
expression were used (gp130F/F). While we are aware of the fact that knockout of gp130 
in adipocytes affects the signaling pathway of all members of the IL-6 cytokines, it still 
seems to be an adequate mouse model to investigate our hypothesis as the mIL-6R is 
not expressed in adipocytes (7), precluding cell-specific depletion of IL-6 signaling in 
adipocytes similar to liver-specific IL-6R knockout mice (13). As expected, gp130 protein 
levels were highly reduced in isolated adipocytes of gp130∆adipo mice, decreased in white 
adipose tissue (WAT), which also contains non-adipocyte cell types, but unchanged in 
skeletal muscle and liver compared to control mice (Figure 1A). To induce obesity, 6 
weeks old mice were either fed a control chow or a HFD for 12 weeks. As expected, 
HFD feeding increased body and fat pad weights, whereas lack of IL-6 cytokine 
signaling in adipocytes did not affect body weight or adipogenesis as assessed by fat 
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pad weights and adipocyte size (Figures 1B to 1F). Likewise, protein levels of PPARγ in 
epididymal and mesenteric WAT were similar in both genotypes (data not shown). Thus, 
adipocyte-specific gp130 deficiency did neither affect HFD-induced increase in body and 
fat pad weight nor adipogenesis. 
 
Reduced basal lipolysis and portal FFA levels in obese gp130∆adipo mice 
In order to assess the impact of IL-6 cytokine signaling on lipolytic activity, FFA 
release was analyzed in adipocytes isolated from gp130 knockout and control 
littermates. Compared to chow-fed mice, basal lipolysis was significantly increased in 
epididymal and mesenteric adipocytes of obese control mice (Figures 2A and 2B). 
Importantly, basal FFA release was blunted in mesenteric but not epididymal adipocytes 
isolated from obese gp130∆adipo mice (Figures 2A and 2B), suggesting that IL-6 cytokine 
signaling contributes to enhanced FFA release from mesenteric adipocytes during 
obesity. Functionality of isolated adipocytes was confirmed by increased lipolysis after 
stimulation with the beta-adrenergic receptor agonist isoproterenol in all depots 
examined (Supplemental Figures 1A and 1B). Of note, phosphorylation of ERK was 
significantly reduced in mesenteric but not epididymal WAT of obese knockout mice, 
supporting the notion that IL-6 cytokine-induced lipolysis in vivo is mediated by ERK 
(Figure 2C and 2D) confirming previous findings in adipocytes in vitro (15). Ex vivo 
findings of reduced lipolysis in portally-drained mesenteric adipocytes were confirmed in 
vivo, as the obesity-induced increase in circulating FFA levels was blunted in portal but 
not systemic circulation of knockout mice (Figures 2E and 2F). Importantly and in 
contrast to lipolysis, gp130 depletion did not affect IL-6 mRNA expression in mesenteric 
WAT (Figure 2G), suggesting similar portal delivery of IL-6 to the liver in both genotypes. 
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In addition, there was no major change in transcript levels of the macrophage markers 
CD11b and F4/80 (34) (Fig. 2H), suggesting similar macrophage content between both 
genotypes. Taken together, IL-6 cytokine signaling stimulates lipolysis of portally drained 
mesenteric but not of systemically drained epididymal fat.  
 
Reduced hepatic steatosis in HFD-fed gp130∆adipo mice 
Mesenteric (and omental) adipose tissue is mainly drained via the portal vein to 
the liver (35), where FFAs were previously reported to activate the stress kinase p38 
mitogen-activated protein kinase (MAPK) (36; 37). Supporting such notion, 
phosphorylation of the p38 MAPK was reduced in livers of obese gp130∆adipo mice 
(Figure 3A). In contrast, mRNA expression of suppressor of cytokine signaling 3 
(SOCS3), which can be induced in the liver by IL-6 thereby promoting hepatic insulin 
resistance (38), was similar in HFD-fed gp130∆adipo and control littermates (1.0±0.3 in 
gp130F/F mice vs. 1.2±0.2 in gp130∆adipo mice, p=0.7). In addition, SOCS3 protein levels 
were not different between both groups (Figure 3B). Such finding supports the notion of 
similar portal delivery of IL-6 to the liver in both gp130∆adipo and control mice. Importantly, 
WAT lipolysis is thought to be an important source of FFA leading to hepatic steatosis 
(39). Accordingly, it was suggested that in humans up to 59% of FFA bound in liver 
triglycerides (TG) may arise from plasma FFA (40). In line, the observed reduction of 
mesenteric WAT lipolysis in obese gp130∆adipo mice was associated with a significant 
decrease in hepatic steatosis as determined by total liver lipid and TG content (Figures 
3C and 3D) as well as by histological examination (Figure 3E). Importantly and as 
expected, HFD feeding significantly increased hepatic lipid accumulation (Figures 3C 
and 3D). Of note, circulating TG content was similar between the genotypes (80.5±3.7 
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mg/dl in HFD-fed gp130F/F mice vs. 84.1±3.8 mg/dl in HFD-fed gp130∆adipo mice, p=0.5). 
Besides FFA uptake, hepatic lipid content is influenced by de novo lipogenesis and beta-
oxidation (39-41). Therefore, hepatic mRNA expression of enzymes involved in 
lipogenesis and beta-oxidation were determined in HFD-fed mice, which was similar 
between both genotypes (Figure 3F). Such data further support the assumption that the 
reduced FFA flux is probably responsible for the observed decrease in hepatic lipid 
accumulation of knockout mice. Of note, there was no difference in hepatic mRNA levels 
of IL-6, TNFα and F4/80 suggesting a similar degree of hepatic inflammation in knockout 
and control mice (Figure 3B). 
 
Improved hepatic insulin sensitivity in HFD-fed gp130∆adipo mice 
Steatosis is closely associated with liver insulin resistance that may be also 
affected by WAT lipolysis (39). In this regard, increased portal delivery of FFA may 
induce liver insulin resistance via the accumulation of lipid metabolites and/or hepatic 
acetyl CoA or directly via activation of p38 MAPK (16; 36; 37; 42). Indeed and as 
mentioned above, phosphorylation of p38 MAPK was decreased in livers of obese 
gp130∆adipo (Figure 3A). To assess hepatic insulin sensitivity, hyperinsulinemic-
euglycemic clamp studies were performed. HFD-fed gp130∆adipo mice revealed 
significantly improved insulin sensitivity as determined by higher glucose infusion rate 
(GIR) during hyperinsulinemic-euglycemic clamp studies (Figure 4A and Supplemental 
Figures 2A to 2C). Insulin-induced suppression of endogenous glucose production 
(mainly reflecting hepatic glucose production) was significantly higher in HFD-fed 
gp130∆adipo compared to gp130F/F mice (Figure 4B) indicating improved hepatic insulin 
sensitivity in knockout mice. In contrast, glucose uptake capacity into skeletal muscle 
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was not affected (Figure 4C). In addition, gp130 depletion had no impact on insulin’s 
ability to suppress FFA release from isolated epididymal adipocytes (Figure 4D). In 
contrast and in support of depot-specific differences in adipocyte metabolism with regard 
to IL-6 cytokine action, insulin’s ability to blunt lipolysis was significantly improved in 
mesenteric adipocytes isolated from obese knockout compared to control mice (Figure 
4E). 
 
Positive correlation of omental IL-6 expression with hepatic steatosis and insulin 
resistance in humans 
Similar to observations in rodents, IL-6 expression was elevated in 
visceral/omental compared to subcutaneous fat depots in obese humans (43). 
Moreover, increased omental but not subcutaneous lipolysis was linked to obesity-
induced fatty liver disease in morbidly obese humans (44). To unravel whether IL-6-
induced omental fat lipolysis may contribute to obesity-associated hepatic steatosis and 
insulin resistance, IL-6 mRNA expression was analyzed in adipose tissue of lean (n= 12, 
BMI 24.5±0.2 kg/m²) and overweight or obese (n=51, BMI 34.4±0.8 kg/m²) individuals 
and correlated to liver fat content. Basic clinical characteristics of these subjects are 
provided in Table 1. Supporting previous findings (43), IL-6 mRNA was increased in 
omental, but not subcutanous adipose tissue of obese when compared to lean 
individuals (Figure 5A). Intriguingly, we found a significant positive correlation between 
omental (r=0.31; p<0.05) but not subcutaneous (r=0.09; p=0.49) IL-6 expression and 
hepatic steatosis (Figure 5B and Supplemental Figure 3A). In addition, glucose infusion 
rate (GIR) during hyperinsulinemic-euglycemic clamp studies revealed significant 
negative correlation to omental but not subcutaneous IL-6 mRNA expression (Figure 5C 
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and Supplemental Figure 3B). Of note, there was a significant correlation between liver 
fat content and clamp GIR (r=-0.53, p<0.001). These data support a role for omental IL-6 
in the development of obesity-associated hepatic steatosis as well as insulin resistance 
in humans. 
 
  
Discussion 
The present study suggests that IL-6 signaling-mediated lipolysis may be 
restricted to omental/mesenteric adipose tissue and that it contributes to hepatic insulin 
resistance and steatosis. Such notion is based on the following findings: i. lipolysis from 
mesenteric but not epididymidal adipose tissue is reduced in HFD-fed gp130∆adipo mice 
compared to control littermates; ii. gp130 depletion specifically in adipocytes reduced 
both HFD-induced hepatic insulin resistance and steatosis. 
IL-6 plays complex roles in inflammation and metabolism having both beneficial 
and adverse properties. In support of detrimental effects of IL-6, it was very recently 
shown that IL-6 induces FFA release in obesity, thereby contributing to increased 
hepatic glucose production and, hence, hepatic insulin resistance (16). Our findings 
presented herein would suggest that the IL-6 signaling-mediated increase in lipolysis is 
restricted to the portally drained mesenteric adipose tissue depot since depletion of 
gp130, the common signal transducer of IL-6, reduced FFA release only from isolated 
mesenteric but not epididymal adipocytes. As IL-6 is the gp130 cytokine with the best-
known lipolytic function (9), such finding may be explained by an increased sensitivity of 
mesenteric adipocytes to IL-6-mediated lipolysis. However, IL-6-induced FFA release 
was only slightly elevated in mesenteric compared to epididymal adipocytes isolated 
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from wild-type mice (1.25±0.14 fold in mesenteric vs. 1.12±0.02 fold in epididymal, 
p=0.4). Alternatively, a selective obesity-induced increase in IL-6 content of mesenteric 
WAT may be responsible for the observed difference (17; 18). The later may be the 
result of unique endogenous properties of mesenteric WAT and/or depend on the close 
proximity to the gut leading to more pronounced inflammation in mesenteric/omental 
compared to other fat depots (35). Along this line, the staphylococcal enterotoxin A 
(SEA) was reported to bind to gp130 in adipocytes thereby interfering with insulin 
sensitivity and lipolysis (45). Interestingly, Staphylococcal spp. is detectable in gut 
microbiota and translocation of intestinal bacteria to mesenteric WAT was observed 
upon high fat feeding in mice (46; 47). Clearly, further studies are needed to unravel a 
potential involvement of SEA in obesity-induced adipose tissue lipolysis. 
Besides IL-6, other cytokines signaling via gp130 may have contributed to the 
observed phenotype. Of note, several IL-6 cytokines were shown to individually affect 
differentiation and adipogenesis rendering gp130 a potential therapeutic target to 
combat obesity and its associated diseases (9). Accordingly, it was recently shown that 
blocking IL-6 trans-signaling using a soluble gp130Fc protein reduces obesity-induced 
infiltration of macrophages into adipose tissue (48). We found herein that lack of IL-6 
cytokine signaling in adipocytes had no impact on fat mass and adipocyte size. Such 
observation may suggest that IL-6 cytokine signaling does not affect adipogenesis. 
However, Cre expression in our mouse model was under the control of the adiponectin 
promoter and, hence, only induced during late stages of adipocyte differentiation since it 
is located downstream of C/EBP (49). Thus, potential effects of individual IL-6 cytokines 
on early adipocyte differentiation (9) may not be reflected in gp130∆adipo mice. 
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Chronically elevated circulating IL-6 levels were proposed to contribute to obesity-
associated hepatic inflammation and insulin resistance in mice (11; 12). In contrast, IL-6 
was recently reported to reduce inflammation and to improve insulin sensitivity in liver 
(13). Our findings may propose an indirect negative impact of IL-6 on hepatic insulin 
resistance and steatosis through induction of adipose tissue lipolysis mainly in 
mesenteric/omental fat depots. Accordingly, depletion of IL-6 cytokine signaling in 
adipocytes reduced portal FFA concentration and improved hepatic lipid accumulation 
as well as insulin resistance in mice. Moreover, omental (but not subcutaneous) IL-6 
expression correlated with hepatic steatosis and insulin resistance in humans. Since it 
was recently shown that increased omental (but not subcutaneous) lipolysis was linked 
to obesity-induced fatty liver disease in morbidly obese humans (44) and that visceral 
lipolysis may contribute significantly to the portal delivery of FFA to the liver (50) our 
proposed mechanism may be conserved between species. Besides reduced lipolysis, 
lower intestinal absorption of FFA (35) or increased fatty acid uptake by adipocytes may 
have contributed to decreased portal FFA levels in HFD-fed gp130∆adipo mice. While our 
data suggest that increased mesenteric FFA release into the portal vein impairs liver 
metabolism, such direct link may be questioned (51). Clearly, changed release of other 
non-FFA factors into portal and/or systemic circulation may have also contributed to the 
observed hepatic phenotype in obese gp130∆adipo mice.  
In conclusion, the obesity-associated rise in mesenteric/omental adipose tissue 
IL-6 cytokine signaling promotes FFA release into the portal circulation inducing hepatic 
steatosis and/or insulin resistance. Hence, blocking IL-6 cytokine signaling in adipocytes 
may be a novel approach to blunt detrimental fat-liver crosstalk in obesity. To this end, 
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the development of cell-specific adeno-associated virus (AAV) vectors may be a 
promising tool in the future (52; 53).  
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Figure Legends 
 
Figure 1 Similar weight gain and adipogenesis in gp130F/F and gp130∆adipo mice 
(A) Western blot analysis of gp130 protein levels in respective cells and tissues of 
gp130F/F and gp130∆adipo mice. (B) Body weight of chow (circles) and HFD-fed (squares) 
gp130F/F and gp130∆adipo mice. n=5-24. Fat pad weights of epididymal (C) and 
mesenteric (D) depots of chow and HFD-fed gp130F/F and gp130∆adipo mice. n=6-18. 
Diameter of epididymal (E) and mesenteric (F) adipocytes of chow (circles) and HFD-fed 
(squares) gp130F/F and gp130∆adipo mice. n=4-6. Results are the means ± SEM. F/F: 
gp130F/F; ∆ad: gp130∆adipo. ***p < 0.001, **p < 0.01, *p < 0.05 (ANOVA).  
 
Figure 2 Reduced basal lipolysis and portal FFA levels in obese gp130∆adipo mice 
Basal FFA release from epididymal (A) and mesenteric (B) adipocytes of chow and 
HFD-fed gp130F/F and gp130∆adipo mice. n=5-10. Protein levels of phospho-ERK, ERK 
and actin in epididymal (C) and mesenteric (D) WAT of HFD-fed gp130F/F and 
gp130∆adipo mice. n=4. FFA concentration was determined in systemic (E) and portal (F) 
plasma samples of chow and HFD-fed gp130F/F and gp130∆adipo mice. n=3-8. IL-6 (G) as 
well as CD11b and F4/80 (H) mRNA expression in mesenteric fat of HFD-fed gp130F/F 
and gp130∆adipo mice. n=6.  Results are the means ± SEM. F/F: gp130F/F; ∆ad: 
gp130∆adipo. ***p < 0.001, **p < 0.01, *p < 0.05 (Student’s t test for Fig. D or ANOVA for 
Figs. A, B, E and F). 
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Figure 3 Reduced hepatic steatosis in HFD-fed gp130∆adipo mice 
(A) Protein levels of phospho-p38 and actin in livers of HFD-fed gp130F/F and gp130∆adipo 
mice. n=10.  (B) Protein levels of SOCS and actin in livers of HFD-fed gp130F/F and 
gp130∆adipo mice. n=6. (C and D) Total liver lipid and liver triglyceride (TG) levels of chow 
and HFD-fed gp130F/F and gp130∆adipo mice. n=4-6. (E) Representative histological 
hematoxylin- and eosin-stained liver sections of HFD-fed gp130F/F and gp130∆adipo mice. 
(F and G) mRNA expression of respective genes in livers HFD-fed gp130F/F and 
gp130∆adipo mice. n=10. Results are the means ± SEM.  F/F: gp130F/F; ∆ad: gp130∆adipo. 
*p < 0.05 (Student’s t test).   
 
Figure 4 Improved hepatic insulin sensitivity in HFD-fed gp130∆adipo mice 
Glucose infusion rate (GIR) (A), endogenous glucose production (EGP) (B) and glucose 
uptake into quadriceps muscle (C) during hyperinsulinemic-euglycemic clamps in HFD-
fed gp130F/F and gp130∆adipo mice. n=4-6. Insulin-inhibited FFA release from epididymal 
(D) and mesenteric (E) adipocytes of HFD-fed gp130F/F and gp130∆adipo mice. n=8-10. 
Results are the means ± SEM. F/F: gp130F/F; ∆ad: gp130∆adipo. **p < 0.01, *p < 0.05 
(Student’s t test).   
 
Figure 5 Positive correlation of omental IL-6 expression with hepatic steatosis 
and insulin resistance in humans 
(A) IL-6 mRNA expression in omental and subcutaneous (sc) white adipose tissue 
(WAT) of lean (n=12) and obese (n=51) human subjects. Omental IL-6 mRNA 
expression correlates with liver fat content (B) and glucose infusion rate (GIR) during the 
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steady state of a euglycemic-hyperinsulinemic clamp (C). Results are the means ± SEM. 
#p=0.11 (Student’s t test). 
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Table 1 Basal clinical characteristics of human subjects 
 
 Lean (n=12) Overweight/Obese (n=51) 
Age (years) 62±12 70±12 
Men/Women (n) 8/4 26/25 
Type 2 diabetes (n) 0 22 
Body mass index (kg/m²) 24.5±0.2 34.4±0.8*** 
Body fat (%) 22.4±0.5 36.7±1.3*** 
Liver fat content (%) 2.0±0.1 22.5±1.8*** 
Fasting plasma 
glucose (mmol/l) 
5.3±0.1 5.7±0.1 
Fasting plasma insulin 
(pmol/l) 
16.8±3.5 204.1±19.1*** 
Glucose infusion rate, clamp 
(µmol/kg/min) 
101.2±3.3 49.7±3.5*** 
HbA1c (%) 5.28±0.05 5.81±0.07*** 
Total cholesterol (mmol/l) 4.42±0.19 5.42±0.12*** 
LDL-cholesterol (mmol/l) 2.74±0.26 3.13±0.13 
HDL-cholesterol (mmol/l) 1.45±0.1 1.32±0.03 
Triglycerides (mmol/l) 0.9±0.12 2.08±0.1*** 
Free fatty acids (mmol/l) 0.38±0.06 0.63±0.04* 
IL-6 (pmol/l) 1.11±0.24 3.87±0.39** 
Adiponectin (ng/ml) 9.27±1.25 4.49±0.35** 
Leptin (ng/ml) 4.75±1.15 26.9±1.91*** 
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*p<0.05, **p<0.01, ***p<0.001 for comparisons between lean and obese individuals. 
Data are given as mean ± SEM. 
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Supplemental Figure 1  
Isoproterenol-stimulated lipolysis in adipose tissue of gp130F/F and gp130adipo mice 
Isoproterenol-stimulated FFA release (fold over basal) from epididymal (A) and mesenteric (B) adipocytes of 
chow and HFD-fed gp130F/F (black bars) and gp130adipo (open bars) mice. n=5-10. Results are the means ± 
SEM.  
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Supplemental Figure 2  
Blood glucose concentrations, glucose infusion rates and plasma insulin levels during 
hyperinsulinemic-euglycemic clamp 
(A) Blood glucose levels were clamped upon insulin infusion at about 5 mmol/l in HFD-fed gp130F/F (black 
circles) and gp130adipo (open circles) mice. n=6. (B) In order to maintain euglycemia, glucose infusion rate 
was adjusted over time in gp130F/F (black circles) and gp130adipo (black circles) mice. n=6. (C) Plasma 
insulin levels after insulin infusion. n=4-5. Results are the means ± SEM.  
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Supplemental Figure 3  
Absent correlation between subcutaneous IL-6 expression and liver fat content 
Subcutaneous IL-6 mRNA expression was determined in lean and obese human subjects and correlated to 
liver fat content (A) and glucose infusion rate (GIR) (B). n= 63.  
Page 34 of 34Diabetes
